The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

For many people suffering from asthma, the winter months and the colder air can trigger asthma symptoms and flare-ups, which ...

MUNICH, Germany I January 30, 2025 I Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced ...

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these ...

The significant increase in ciliated 2 cells in patients experiencing acute asthma exacerbations suggests their potential role in asthma development. We compared the functional annotations of ciliated ...

Nial Wheate in the past has received funding from the ACT Cancer Council, Tenovus Scotland, Medical Research Scotland, Scottish Crucible, and the Scottish Universities Life Sciences Alliance.

Montelukast can't be used to treat acute asthma (an asthma attack), as it takes time for the tablet to be broken down in the stomach and for it to be absorbed into the body. Rather, it's taken ...

A declining trend in the prevalence of cost-related asthma treatment nonadherence was noted among US adults from 2011 to 2022, dropping from 23.2% to 13.1%. Although cost-related nonadherence to ...

has a place in the effort to avert acute attacks; however, its use is restricted within the allergic asthma subtype. The treatment of an already established exacerbation is more straight forward ...